mRNA CDMO Service

The COVID-19 pandemic has pushed mRNA vaccines from a relatively "niche" technology into the mainstream. Compared with other methods, the production process of mRNA through in vitro transcription vaccines can significantly reduce production costs. mRNA vaccines can also robustly promote cellular and humoral immune responses, and regulate the level of immune responses to a certain extent.

Relying on its powerful plasmid platform capabilities, ProBio has established high-quality services in the field of mRNA, providing customers with one-stop solution from plasmids to mRNA, including plasmids, linearized DNA, IVT-mRNA and lipid nanoparticle (LNP) encapsulation. The seamless connection between plasmid and mRNA CMC greatly guarantees the project development cycle, manufacturing process and product quality.